The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

Novel therapies are urgently needed to prevent and treat tyrosine kinase inhibitor resistance in chronic myeloid leukaemia (CML). MLN8237 is a novel Aurora A kinase inhibitor under investigation in multiple phase I and II studies. Here we report that MLN8237 possessed equipotent activity against Ba/...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Kevin R, Ecsedy, Jeffrey, Medina, Ernest, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Nawrocki, Steffan T, Giles, Francis J, Carew, Jennifer S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394217/
https://www.ncbi.nlm.nih.gov/pubmed/21091633
http://dx.doi.org/10.1111/j.1582-4934.2010.01218.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394217/
https://www.ncbi.nlm.nih.gov/pubmed/21091633
http://dx.doi.org/10.1111/j.1582-4934.2010.01218.x

Ejemplares similares